|Company name||GTx, Inc.|
NEW YORK, March 8, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of GTx, Inc. (NASDAQ: GTXI) on behalf of stockholders concerning the proposed merger of the company with Oncternal Therapeutics, Inc.
Pursuant to the proposed transaction, announced on March 7, 2019, current GTx stockholders will own approximately 25% of the combined company. The investigation focuses on whether GTx and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own GTx shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.